Royalty Pharma (RPRX)

This model gives Royalty Pharma exposure to the economics of major therapies without operating laboratories, running large sales forces, or manufacturing drugs itself. Its portfolio includes royalty streams tied to widely used products across oncology, immunology, neurology, rare diseases, and other therapeutic areas. Examples include royalties linked to Imbruvica, used in certain blood cancers, Tysabri for multiple sclerosis, and Vertex’s cystic fibrosis treatments.

The company also invests in development-stage candidates, which can add long-term upside if those medicines reach the market. That strategy makes Royalty Pharma a capital provider to the life sciences sector, helping fund innovation while seeking future cash flows from successful products.

For investors, RPRX differs from a conventional pharmaceutical stock because its performance depends on the breadth and durability of royalty streams across many products rather than the commercial execution of a single drug company. Key factors include prescription trends, patent life, competition from newer therapies or generics, regulatory outcomes, and the company’s ability to source attractive new royalty deals.